TAK

Takeda PharmaceuticalC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$19.50

+28.5% vs current

Most likely

Base case

60%

Probability

Target price

$17.00

+12.0% vs current

B-

Bear case

20%

Probability

Target price

$14.87

-2.0% vs current

AI sentiment snapshot

Latest data as of 2026-01-30

AI commentary

Consensus targets cluster around the current price with a median near the mid-$16s and a high near $19.5, implying limited near-term upside from the anchor absent positive clinical or regulatory news. Market tone is neutral-to-cautious; upside is contingent on successful readouts, credible guidance, and execution on cost synergies.

RankAlpha Sentiment AI - 2026-01-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30eventNext quarterly results (assumed window)Medium impact

Next quarterly earnings release; no firm date published in reviewed sources so a conservative estimate is used (assumed end of window) — market reactions likely to reprice guidance and analyst targets [#SERP-1].

2026-04-30catalystAnalyst target revisionsHigh impact

Analyst target updates following earnings or guidance changes; current scraped targets show a tight median/high range that could be nudged by results or guidance shifts [#SERP-1], [#SERP-3].

2027-01-30catalystPipeline readouts and strategic executionHigh impact

Longer-term clinical readouts and portfolio/efficiency execution could materially alter valuation over the next year; timeline conservatively set one year out when specific dates are not publicly disclosed.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-30 • Updated nightlySource: Internal modelMethodology